- Home
- GYRE vs XPEL Comparison
GYRE vs XPEL Comparison
Compare GYRE & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- XPEL
- Stock Information
- Founded
- GYRE 2002
- XPEL 1999
- Country
- GYRE United States
- XPEL United States
- Employees
- GYRE N/A
- XPEL N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- GYRE Health Care
- XPEL Industrials
- Exchange
- GYRE Nasdaq
- XPEL Nasdaq
- Market Cap
- GYRE 897.1M
- XPEL 999.3M
- IPO Year
- GYRE N/A
- XPEL N/A
- Fundamental
- Price
- GYRE $7.42
- XPEL $36.06
- Analyst Decision
- GYRE
- XPEL Strong Buy
- Analyst Count
- GYRE 0
- XPEL 1
- Target Price
- GYRE N/A
- XPEL $58.00
- AVG Volume (30 Days)
- GYRE 253.7K
- XPEL 172.1K
- Earning Date
- GYRE 08-12-2025
- XPEL 08-07-2025
- Dividend Yield
- GYRE N/A
- XPEL N/A
- EPS Growth
- GYRE N/A
- XPEL N/A
- EPS
- GYRE 0.02
- XPEL 1.71
- Revenue
- GYRE $100,643,000.00
- XPEL $434,101,000.00
- Revenue This Year
- GYRE $21.04
- XPEL $11.20
- Revenue Next Year
- GYRE $89.64
- XPEL $11.18
- P/E Ratio
- GYRE $93.77
- XPEL $21.04
- Revenue Growth
- GYRE N/A
- XPEL 8.38
- 52 Week Low
- GYRE $6.11
- XPEL $24.25
- 52 Week High
- GYRE $19.00
- XPEL $48.58
- Technical
- Relative Strength Index (RSI)
- GYRE 39.71
- XPEL 49.31
- Support Level
- GYRE $7.26
- XPEL $35.35
- Resistance Level
- GYRE $8.00
- XPEL $36.57
- Average True Range (ATR)
- GYRE 0.49
- XPEL 1.04
- MACD
- GYRE -0.07
- XPEL -0.32
- Stochastic Oscillator
- GYRE 10.36
- XPEL 26.37
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.